KR20200143634A - 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자 - Google Patents

탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자 Download PDF

Info

Publication number
KR20200143634A
KR20200143634A KR1020197024980A KR20197024980A KR20200143634A KR 20200143634 A KR20200143634 A KR 20200143634A KR 1020197024980 A KR1020197024980 A KR 1020197024980A KR 20197024980 A KR20197024980 A KR 20197024980A KR 20200143634 A KR20200143634 A KR 20200143634A
Authority
KR
South Korea
Prior art keywords
seq
her2
cell
shiga toxin
targeting molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197024980A
Other languages
English (en)
Korean (ko)
Inventor
에릭 포마
에린 윌렛
잭 히긴스
Original Assignee
몰레큘러 템플레이츠, 인코퍼레이션.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 몰레큘러 템플레이츠, 인코퍼레이션. filed Critical 몰레큘러 템플레이츠, 인코퍼레이션.
Publication of KR20200143634A publication Critical patent/KR20200143634A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02022—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2) rRNA N-glycosylase (3.2.2.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020197024980A 2018-04-17 2019-04-16 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자 Ceased KR20200143634A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659116P 2018-04-17 2018-04-17
US62/659,116 2018-04-17
PCT/US2019/027627 WO2019204272A1 (en) 2018-04-17 2019-04-16 Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds

Publications (1)

Publication Number Publication Date
KR20200143634A true KR20200143634A (ko) 2020-12-24

Family

ID=66324008

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197024980A Ceased KR20200143634A (ko) 2018-04-17 2019-04-16 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자

Country Status (10)

Country Link
US (3) US11225509B2 (https=)
EP (1) EP3573652A1 (https=)
JP (2) JP7323200B2 (https=)
KR (1) KR20200143634A (https=)
CN (1) CN110612117B (https=)
AU (1) AU2019257343A1 (https=)
CA (1) CA3097178A1 (https=)
IL (1) IL268443B2 (https=)
MX (1) MX2019009726A (https=)
WO (1) WO2019204272A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909278B (zh) 2014-01-27 2024-04-09 分子模板公司 Mhc i类表位递送多肽
WO2018106895A1 (en) * 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
WO2020154475A1 (en) * 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains
US20230295342A1 (en) * 2020-07-22 2023-09-21 Eric POMA Clinical methods for use of her2 binding molecules
CN112755173B (zh) * 2020-12-31 2022-01-07 深圳市科达顺生物技术有限公司 用于治疗三阴性乳腺癌的Ii-Key/HER2杂交多肽药物及其制备方法
CN120603855A (zh) * 2022-12-01 2025-09-05 百立特生物制药有限公司 抗her2/trop2抗体及其用途
JP7762994B1 (ja) * 2024-08-07 2025-10-31 株式会社Hyperion Drug Discovery 新規接着分子

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080898A (en) 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
DE69031120T2 (de) 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
WO1991009871A1 (en) 1989-12-22 1991-07-11 Seragen Incorporated Hybrid molecules having translocation region and cell-binding region
US5578482A (en) 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
US5635384A (en) 1990-06-11 1997-06-03 Dowelanco Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994026910A1 (en) 1993-05-12 1994-11-24 Xoma Corporation Immunotoxins comprising gelonin and an antibody
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
EP0655924A4 (en) 1992-06-30 1996-09-11 Oncologix Inc A COMBINATION OF MONOCLONAL ANTIBODIES AGAINST erbB-2 AND METHOD FOR THEIR USE.
FR2697695B1 (fr) 1992-11-04 1995-01-13 Cachan Ecole Normale Superieur Dispositif de conversion électromécanique produisant un mouvement en particulier linéaire.
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
AU5431196A (en) 1995-03-24 1996-10-16 Ophidian Pharmaceuticals Treatment for verotoxin-producing escherichia coli
US5667786A (en) 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
CA2245835A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5858682A (en) 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
EP0921167A4 (en) 1996-08-22 2000-01-12 Kaneka Corp CURABLE COMPOSITION FOR EXTERIOR COATING AND ARTICLES THEREOF COVERED
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
WO1998011229A2 (en) 1996-09-10 1998-03-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
FR2766193B1 (fr) 1997-07-18 2001-09-14 Inst Curie Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
CA2222993A1 (en) 1998-02-04 1999-08-04 The Ontario Cancer Institute A method for using a ribosome-inactivating protein complex as a structural template and a molecular search engine in the design, construction and screening of combinatorial protein libraries
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
ES2205849T3 (es) 1998-07-22 2004-05-01 Osprey Pharmaceuticals Limited Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares.
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
WO2000020579A1 (en) 1998-10-02 2000-04-13 Mcmaster University Spliced form of erbb-2/neu oncogene
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2001001748A2 (en) 1999-07-02 2001-01-11 Genentech, Inc. Peptide compounds that bind her2
US6492498B1 (en) 1999-11-15 2002-12-10 Regents Of The University Of Minnesota Multimeric immunotoxins
US7267973B2 (en) 2000-03-22 2007-09-11 Sibtech, Inc. Nucleic acids encoding recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor
US20010031485A1 (en) 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2003055439A2 (en) 2001-07-18 2003-07-10 The Regents Of The University Of California Her2/neu target antigen and use of same to stimulate an immune response
WO2003066854A1 (fr) 2002-02-04 2003-08-14 Yoshida, Hideo Agent anticancereux utilisant des variantes de verotoxines
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US7435797B2 (en) 2002-04-10 2008-10-14 Genentech, Inc. Anti-HER2 antibody variants
US7449480B2 (en) 2002-05-14 2008-11-11 Baylor College Of Medicine Small molecule inhibitors of HER2 expression
US7019017B2 (en) 2002-05-14 2006-03-28 Baylor College Of Medicine Small molecule inhibitors of HER2 expression
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
US7875586B2 (en) 2002-12-20 2011-01-25 The Johns Hopkins University Treatment of metastatic colon cancer with b-subunit of shiga toxin
AU2003294023B2 (en) 2003-01-03 2008-01-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Rhesus HER2/neu, nucleotides encoding same, and uses thereof
WO2005000902A1 (en) 2003-06-30 2005-01-06 Mu-Hyeon Choe The dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
US7993650B2 (en) 2003-07-04 2011-08-09 Affibody Ab Polypeptides having binding affinity for HER2
JP2007517763A (ja) 2003-08-01 2007-07-05 エイアンドジー ファーマスーティカル インコーポレイテッド Ｈｅｒ２アンタゴニストを用いた治療への感受性を回復させる組成物および方法
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7982011B2 (en) 2003-11-25 2011-07-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
EP1687016A4 (en) 2003-11-25 2009-07-29 Anjin Corp GENETIC VARIANT OF DIPHTHERIC TOXIN
US20070298434A1 (en) 2004-03-26 2007-12-27 Jean Gariepy Library of Toxin Mutants, and Methods of Using Same
KR20140032004A (ko) 2004-07-22 2014-03-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US7771955B2 (en) 2005-06-09 2010-08-10 University Of Maryland Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
FI20055417A0 (fi) 2005-07-20 2005-07-20 Glykos Finland Oy Syöpäpesifiset glykaanit ja niiden käyttö
JP2009502936A (ja) 2005-07-25 2009-01-29 トルビオン ファーマシューティカルズ， インコーポレイテッド Ｃｄ２０特異的結合分子の単一投与量
ES2493465T3 (es) 2005-09-26 2014-09-11 Molecular Templates, Inc. Biblioteca a partir de toxinas mutantes y procesos de utilización de la misma
JP2009520468A (ja) 2005-12-23 2009-05-28 ヴィヴェンティア バイオテック インコーポレーティッド 融合タンパク質ライブラリーの作製法およびスクリーニング法、ならびにそれらの使用
JP5409014B2 (ja) 2006-02-16 2014-02-05 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 志賀トキソイドキメラタンパク質
BRPI0720647A2 (pt) 2006-12-29 2014-01-14 Osprey Pharmaceuticals Usa Inc Processos de seleção e produção de toxinas modificadas, conjugados contendo toxinas modificadas e usos dos mesmos
ES2798758T3 (es) 2007-06-06 2020-12-14 Sarepta Therapeutics Inc Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades
JP2010530895A (ja) 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
US7887801B2 (en) 2007-07-13 2011-02-15 Topotarget Germany Ag Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
WO2009017823A2 (en) 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health A fold-back diabody diphtheria toxin immunotoxin and methods of use
PL2197903T3 (pl) 2007-09-04 2015-03-31 Us Gov Health & Human Services Delecje w domenie ii egzotoksyny a psuedomonas zmniejszające toksyczność niespecyficzną
WO2009088403A2 (en) 2007-10-08 2009-07-16 Rutgers, The State University Nontoxic shiga-like toxin mutant compositions and methods
CA2705289A1 (en) 2007-11-13 2009-05-22 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
EP2220120A2 (en) 2007-11-27 2010-08-25 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
JP5337815B2 (ja) 2007-12-17 2013-11-06 アンワイヤード プラネット エルエルシー 多アンテナ受信機干渉除去方法及び装置
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
EP2268297A4 (en) 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
ES2342646B1 (es) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
JP6049163B2 (ja) 2008-07-21 2016-12-21 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 改善された治療上の特徴のための抗体の構造変異体
US20110280913A1 (en) 2008-07-31 2011-11-17 The Ohio State University Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders
US20100093563A1 (en) 2008-09-22 2010-04-15 Robert Anthony Williamson Methods and vectors for display of molecules and displayed molecules and collections
KR101832499B1 (ko) 2009-01-23 2018-02-26 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 시가 독소 2형 단백질 기반 방법 및 조성물
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
US20120258104A1 (en) 2009-07-22 2012-10-11 Cenix Bioscience Gmbh Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes
EP2464836A2 (en) 2009-08-14 2012-06-20 Unifrax I LLC Mounting mat for exhaust gas treatment device
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
KR20130108069A (ko) 2010-04-15 2013-10-02 알퍼 바이오테크, 엘엘씨 Ｈｅｒ2 항원에 대한 모노클로날 항체 및 그를 위한 용도
CN114805583A (zh) 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
PL219845B1 (pl) 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
CA2825023A1 (en) 2011-01-26 2012-08-02 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
WO2012104344A1 (en) 2011-02-01 2012-08-09 Genmab A/S Human antibodies and antibody-drug conjugates against cd74
US8895006B2 (en) 2011-03-04 2014-11-25 Rutgers, The State University Of New Jersey Ricin ribosome binding protein compositions and methods of use thereof
RU2600067C2 (ru) 2011-05-06 2016-10-20 Дзе Гавермент Оф Дзе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Дзе Секретари Оф Дзе Депармент Оф Хелс Энд Хьюман Сёрвисез Рекомбинантный иммунотоксин, нацеленный на мезотелин
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
EP2817341A4 (en) 2012-02-23 2015-12-02 Harvard College MICROBIAL MODIFIED TOXIN RECEPTOR FOR THE DISTRIBUTION OF AGENTS IN CELLS
RS60280B1 (sr) 2013-03-12 2020-06-30 Molecular Templates Inc Citotoksični proteini koji sadrže ciljane vezujuće regione za ćelije i regioni shiga toksina a podjedinice za selektivno ubijanje određenih vrsta ćelija
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US20160177284A1 (en) 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
CN111909278B (zh) 2014-01-27 2024-04-09 分子模板公司 Mhc i类表位递送多肽
WO2017019623A2 (en) * 2015-07-26 2017-02-02 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
US20210138076A2 (en) 2014-01-27 2021-05-13 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
US10421958B2 (en) 2014-02-05 2019-09-24 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
AU2015229583B2 (en) 2014-03-11 2020-07-09 Molecular Templates, Inc. Proteins comprising amino-terminal proximal Shiga toxin A Subunit effector regions and cell-targeting immunoglobulin-type binding regions
ES2723774T3 (es) 2014-03-11 2019-09-02 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
JP6643545B2 (ja) 2014-03-14 2020-02-12 ラクオリア創薬株式会社 Ｔｒｐｍ８拮抗剤としてのアザスピロ誘導体
ES2919749T3 (es) 2014-06-11 2022-07-28 Molecular Templates Inc Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa
EP3157958B1 (en) 2014-06-18 2020-05-06 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Car-expressing nk-92 cells as cell therapeutic agents
CN105713087B (zh) 2014-11-12 2020-05-08 北京康乐卫士生物技术股份有限公司 人乳头瘤病毒58型单克隆抗体及其应用
MX2017010072A (es) 2015-02-05 2017-11-09 Molecular Templates Inc Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
KR102357312B1 (ko) 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
AU2016271124C1 (en) * 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3202783A1 (en) 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
KR102418372B1 (ko) 2016-03-29 2022-07-08 주식회사 에스티큐브 글리코실화된 pd-l1에 특이적인 이중 기능 항체 및 이의 사용 방법
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CN117088979A (zh) 2016-10-30 2023-11-21 上海复宏汉霖生物技术股份有限公司 抗-pd-l1抗体及变异体
WO2018106895A1 (en) * 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
WO2018124642A2 (ko) 2016-12-26 2018-07-05 단국대학교 천안캠퍼스 산학협력단 치수줄기세포의 상아 모전구세포로의 분화용 조성물 및 상아모전구세포 표면에 특이적으로 결합하는 IgG 또는 IgM 타입 단일 클론 항체
AU2018211064A1 (en) 2017-01-18 2019-09-05 Genentech, Inc. Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof
EP3573648B1 (en) 2017-01-25 2023-11-22 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
US20200190138A1 (en) 2017-02-28 2020-06-18 Chugai Seiyaku Kabushiki Kaisha Protein purification with protein l
BR112019018533A2 (pt) 2017-03-09 2020-04-14 Genmab A/S anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, método para tratar uma doença, e, uso de um anticorpo
BR112019020185A2 (pt) 2017-03-27 2020-06-02 Celgene Corporation Métodos e composições para redução da imunogenicidade
CN111108113B (zh) 2017-09-25 2024-02-23 Jsr株式会社 免疫球蛋白结合蛋白质和使用其的亲和载体
WO2019183093A1 (en) 2018-03-19 2019-09-26 Abeome Corporation High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains

Also Published As

Publication number Publication date
IL268443B1 (en) 2024-03-01
JP2021531732A (ja) 2021-11-25
CA3097178A1 (en) 2019-10-24
US20230331785A1 (en) 2023-10-19
IL268443A (en) 2020-01-30
US11225509B2 (en) 2022-01-18
AU2019257343A1 (en) 2020-09-10
CN110612117B (zh) 2024-04-12
IL268443B2 (en) 2024-07-01
WO2019204272A1 (en) 2019-10-24
CN110612117A (zh) 2019-12-24
US20220162271A1 (en) 2022-05-26
US20210040160A1 (en) 2021-02-11
MX2019009726A (es) 2020-02-05
JP7323200B2 (ja) 2023-08-08
EP3573652A1 (en) 2019-12-04
JP2023156309A (ja) 2023-10-24

Similar Documents

Publication Publication Date Title
US20220354938A1 (en) Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
US11225509B2 (en) HER2-targeting molecules comprising de-immunized, Shiga toxin A subunit scaffolds
KR102647100B1 (ko) 탈면역된 시가 독소 a 서브유닛 스캐폴드 및 이를 포함하는 세포-표적화 분자
AU2020260425A1 (en) Protease-cleavage resistant, Shiga toxin A Subunit effector polypeptides and cell-targeted molecules comprising the same
US11136395B2 (en) PD-L1 -binding molecules comprising Shiga toxin A subunit scaffolds
US11918649B2 (en) PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
HK1246309B (en) De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190826

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220308

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240923

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241202

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D